Antiplatelet Agents Added to Aspirin: No Benefit for SVG Patency After CABG

Affiliations

Editorial

Steven Goldman. Circulation. 2020.

. 2020 Nov 10;142(19):1808-1809.

doi: 10.1161/CIRCULATIONAHA.120.050879. Epub 2020 Aug 31.

¹ C. Leonard Pfeiffer Endowed Professor of Cardiovascular Research, Sarver Heart Center, University of Arizona, Tucson.

No abstract available

Keywords: Editorials; aspirin; platelet aggregation inhibitors; ticagrelor.

Comment on

Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial.
Willemsen LM, Janssen PWA, Peper J, Soliman-Hamad MA, van Straten AHM, Klein P, Hackeng CM, Sonker U, Bekker MWA, von Birgelen C, Brouwer MA, van der Harst P, Vlot EA, Deneer VHM, Chan Pin Yin DRPP, Gimbel ME, Beukema KF, Daeter EJ, Kelder JC, Tijssen JGP, Rensing BJWM, van Es HW, Swaans MJ, Ten Berg JM. Willemsen LM, et al. Circulation. 2020 Nov 10;142(19):1799-1807. doi: 10.1161/CIRCULATIONAHA.120.050749. Epub 2020 Aug 31. Circulation. 2020. Retracted and republished in: Circulation. 2021 Jul 13;144(2):e36. doi: 10.1161/CIR.0000000000001004. PMID: 32862716 Retracted and republished. Clinical Trial.